Xencor
Xencor is a clinical-stage biopharmaceutical company engineering engineered antibody and cytokine therapeutics using its XmAb and XenLock platforms. The pipeline spans XmAb819 (Phase 1, advanced clear cell renal cell carcinoma; oral presentation at ESMO 2026), plamotamab (a CD20 x CD3 bispecific in non-Hodgkin lymphoma partnered with Janssen), XmAb541 (a CLDN18.2 x 4-1BB bispecific), XmAb662 (a PD-1 x IL-15 fusion), and vudalimab (a PD-1 x CTLA-4 bispecific). The company's royalty revenues from Ultomiris (ravulizumab), Monjuvi (tafasitamab) and other partnered programs have funded an extended clinical-development runway and the 2024 strategic refocus on wholly owned oncology assets.
Company Info
Upcoming Milestones & Key Dates
XmAb819 Phase 1 oral presentation in advanced clear cell renal cell carcinoma
Plamotamab Phase 1/2 updates expected
Clinical Development Pipeline
XmAb819
Target: CD70 x CD3 engineered bispecific antibody (XmAb 2+1 format)Plamotamab
Target: CD20 x CD3 bispecific antibody (Janssen partnership)Vudalimab
Target: PD-1 x CTLA-4 bispecific antibodyXmAb541
Target: CLDN18.2 x 4-1BB bispecific antibodyXmAb662
Target: PD-1 x IL-15 receptor fusion proteinRecent News
No recent news updates available for this company.
Leadership Team
Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer and Co-Founder
Careers & Job Openings